It's a great question and I have looked into it some.
It's a great question and I have looked into it some. Everything I've read, and please correct me if I am wrong, says that lenacapavir is specific to the HIV capsid and will be a subcutaneous injection every 6 months alongside an additional antiviral regimen. The side effects aren't horrible but they aren't as limited as ours.
But to me, if I had to make a decision on treatments, I want leronlimab. You are not only preventing HIV from binding but think of all the other diseases you may be preventing and conditions you may be positively impacting. I see HIV as a catalyst that helps us realize our potential. It may be what leronlimab was developed for but given all the conditions this could positively impact and potentially prevent from occurring, why wouldn't you want to get the many additional positive impacts of leronlimab? Psoriasis, MS, Alzheimers, Cancer, post-viral, etc. Granted it needs to be proven before we can state these for certain, but it's not as though we are pulling these out of a hat...there are years of research to back these indications up.
I know we have heard testimonials from HIV patients in the past but I would love to hear their experience with other diseases while on 700mg of leronlimab. Do some of these other indications we are pursuing occur with less of a frequency? It would be really interesting to know.
We should hopefully find out more on lenacapavir next week as they are presenting their trial data at the AIDS Society Conference on HIV Science but I like our drug better due to the potential for positive effects it likely has. Leronlimab's stats with HIV are pretty impressive too so it will be interesting to compare when we have the data.
9
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Look Who's Lining Up for Chinese Pastries Alright, here we go. China's baking scene is pulling in audiences far and wide, as if the whole world suddenly caught a whiff of their freshest, steaming buns. The 11th Bakery China Autumn, recently wrapped up at the Wuhan International Expo Center, saw a 50% rise in international buyers. This stat gives you that warm and cozy...
Continue Reading
Medicare's CJR-X Challenges Hospitals 2028 is setting up to be a year hospitals across the U.S. remember, not with a smile, but likely with clenched teeth. Medicare's CJR-X model is ready to put about 2,217 hospitals in a financial vise over hip, knee, and ankle replacements. Going into effect on January 1, 2028, this mandate turns health networks' profit dreams into a...
Continue Reading
WareSpace's National Growth Strategy: A New Expansion Chapter They say everything's bigger in Texas, but WareSpace is showing that smaller can be mighty impactful too. With its shrewd acquisition of sites in Houston's Inner Loop and Fremont's Warm Springs corridor, WareSpace is playing it smart, appeasing that roaring demand for tiny but mighty warehouse spaces across...
Continue Reading
Five Lawyers, One Prestigious List Eating lunch today, I nearly dropped my sandwich when I read that five top-notch attorneys from Greenberg Traurig have snagged spots on Delaware Today's 2026 Top Lawyers List. This isn't your everyday pat on the back; it's Delaware, the heavyweight champ of corporate law, after all. The Legal Eagles of Greenberg Traurig Kicking off this...
Continue Reading
Sitting at the Crossroads of M&A Scrutiny Alright, it's time to put on our skeptical hats. Out in the world of mergers and acquisitions, not every deal glimmers with gold. You've got FG Imperii Acquisition Corp. (NASDAQ: FGII) under the lens, with a merger alongside tZERO Group, Inc. stirring up a storm. The folks over at Monteverde & Associates, an M&A Class Action Firm...
Continue Reading
Xi's Blueprint for Financial Strength Xi Jinping isn't just whistling Dixie when it comes to reshaping China's financial landscape. His vision is about more than pushing paper; it's about embedding honesty, prudence, and traditional values into the very DNA of China's financial sector. When he talks about enhancing both hard and soft power, he’s thinking wider than...
Continue Reading
Coretek's Leap to AI Innovator Status Here we are, folks. Another announcement hits the wires that showcases a company's ascent amid the swelling AI tide. Coretek, hailing from Farmington Hills, managed to snag a spot on CRN's inaugural 2026 AI Innovators list. No small potatoes, if you ask me, considering the competition on this playing field. Why the fuss? It's about...
Continue Reading
MSA's Stellar Growth Amidst Strategic Shifts Ah, the rush of quarterly results, and today we're eyeballing MSA Safety's third quarter of 2026. If numbers light your fire, MSA's boasting some scorching ones right now. The company's net sales shot up to $536 million—a 15% leap from the previous year. Now, in this dog's game of margins and market maneuvers, that's a solid...
Continue Reading
A Sneak Peek into Yuhang's Technological Leap Imagine strolling through a place where technology and nature coexist in harmony. That's exactly what journalists from around the globe got to experience during their recent jaunt to Yuhang District in Hangzhou. We're talking about reps from South Korea, Turkey, the U.S., and even Cuba getting a firsthand look at Yuhang's...
Continue Reading
GNSS Simulator Market: Gadgets Meet Growth A market that's been quietly bubbling away on the back burner is about to boil over: The GNSS Simulator Market, pegged at a neat $424.6 million by 2031. Yeah, it might be niche, but those in the know can't get enough of these satellite-signal replicators. Why GNSS Simulators are Crushing It There's a bunch of reasons why GNSS...
Continue Reading
Top 5 Most Recently Viewed Articles
LBJ Express: A Milestone in Infrastructure and Mobility The LBJ Express marks a significant milestone, celebrating its tenth anniversary as a transformative project that has improved mobility and fostered economic growth in the region. Originally opened in September 2015, this impressive 13-mile corridor runs from Interstate 35E through to U.S. 75 along the busy...
Continue Reading
Understanding the Rising Cosmetic Manufacturing Market As we dive into the world of beauty and aesthetics, one cannot overlook the vast potential within the cosmetic manufacturing industry. A recent report highlights that the global revenue from the cosmetic manufacturing sector is set to experience significant growth, with projections estimating a remarkable valuation of...
Continue Reading
Market Resilience Amid Liquidity and Buyback Activities The current state of the market presents an intriguing picture, balancing risks while feeling surprisingly secure. It's akin to gliding on a fortified layer of fiscal stability, supported by strong monetary influences and persistent retail investments. Recent fluctuations seem to serve merely as a trial of market...
Continue Reading
AirSculpt Technologies Reports First Quarter Fiscal 2025 Results AirSculpt Technologies, Inc. (NASDAQ:AIRS), recognized as a national leader in premium body contouring procedures, has shared its financial performance for the first quarter. Despite some challenges, the company is poised for future growth as it continues to innovate in the field of body aesthetics....
Continue Reading
Winshear Gold Corp's Strategic Earn-In Agreement Winshear Gold Corp. (TSXV: WINS) is making waves in the mineral exploration industry with its newly announced agreement concerning the notable Thunder Bay Gold Project (TBGP). The company, headquartered in Vancouver, is set to earn a 100% interest in the expansive 360 square kilometers of the Thunder Bay region, a site that...
Continue Reading